
Latest News
Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones
July 7, 2026
Fragility fractures are a major and growing health burden, with significant personal and economic consequences, requiring urgent action for improved prevention and early identification.
In a new study from McMaster University, published in Scientific Reports, researchers compared multiple machine learning models to predict fragility fracture risk using established clinical and lifestyle risk factors. The work also highlights the key factors that are potentially associated with fracture risk.
The study was led by ASM (Sayem) Borhan, assistant professor in the Department of Health Research Methods, Evidence, and Impact (HEI), and member of the McMaster Institute for Research on Aging (MIRA). Accompanying HEI contributors include distinguished university professors, Parminder Raina and Lehana Thabane, who are also affiliated with MIRA as Director and member, respectively.
The findings will help identify individuals at higher risk and reinforce opportunities for earlier, targeted prevention strategies that could reduce both patient and health system impacts.
The study was partially funded by a fellowship award from Osteoporosis Canada and the Canadian Multicentre Osteoporosis Study.
Visit the webpage for the Department of Health Research Methods, Evidence, and Impact (HEI) on the McMaster website for the full story and to learn more: https://hei.healthsci.mcmaster.ca/researchers-use-machine-learning-to-better-predict-fractures-caused-by-weak-bones/
OC MAKES THE NEWS – RECENT ITEMS
Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones
Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]
INESSS in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section
Latest News INESSS in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section June 23, 2026 INESSS (the Institut national d’excellence en […]
Health Canada Approves of DENOZA™, a Denosumab Biosimilar
Latest News Health Canada Approves of DENOZA™, a Denosumab Biosimilar May 5, 2026 Apotex Inc., a Canadian based global pharmaceutical company announced that Health Canada has approved DENOZA™ (denosumab injection), […]